LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

Search

Pfizer

Fermé

SecteurSoins de santé

27.37 -0.73

Résumé

Variation du prix de l'action

24h

Actuel

Min

27.2

Max

27.84

Chiffres clés

By Trading Economics

Revenu

-5.2B

-1.6B

Ventes

903M

18B

P/E

Moyenne du Secteur

19.89

121.746

BPA

0.66

Rendement du dividende

6.32

Marge bénéficiaire

-9.387

Employés

81,000

EBITDA

-6.6B

-930M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+4.46% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

6.32%

2.26%

Prochains Résultats

28 avr. 2026

Date du Prochain Dividende

6 mars 2026

Date du Prochain Détachement de Dividende

8 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

2.2B

154B

Ouverture précédente

28.1

Clôture précédente

27.37

Sentiment de l'Actualité

By Acuity

39%

61%

116 / 351 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Pfizer Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 févr. 2026, 12:25 UTC

Résultats

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

20 janv. 2026, 10:40 UTC

Acquisitions, Fusions, Rachats

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments -- Update

20 janv. 2026, 07:47 UTC

Acquisitions, Fusions, Rachats

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

10 févr. 2026, 21:51 UTC

Résultats

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 févr. 2026, 21:17 UTC

Résultats

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

3 févr. 2026, 21:36 UTC

Résultats

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3 févr. 2026, 19:56 UTC

Résultats

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 févr. 2026, 19:46 UTC

Résultats

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3 févr. 2026, 17:35 UTC

Résultats

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 févr. 2026, 17:30 UTC

Résultats

These Stocks Are Today's Movers: Palantir, PayPal, Novo Nordisk, Pfizer, Merck, AMD, Gartner, and More -- Barrons.com

3 févr. 2026, 13:50 UTC

Résultats

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 févr. 2026, 13:06 UTC

Résultats

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 févr. 2026, 12:45 UTC

Résultats

These Stocks Are Today's Movers: Palantir, PayPal, Teradyne, Tesla, Pfizer, AMD, Merck, and More -- Barrons.com

3 févr. 2026, 12:02 UTC

Résultats

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 févr. 2026, 11:48 UTC

Résultats

Pfizer: About 20 Key Pivotal Study Starts Planned for 2026 >PFE

3 févr. 2026, 11:48 UTC

Résultats

Pfizer: Enters 2026 With Clear Strategic Priorities, Growing Late-Stage Pipeline >PFE

3 févr. 2026, 11:47 UTC

Résultats

Pfizer: Current Financial Guidance Doesn't Anticipate Any Stock Buybacks in 2026 >PFE

3 févr. 2026, 11:46 UTC

Résultats

Pfizer Sees 2026 Adjusted R&D Expenses $10.5B-$11.5B >PFE

3 févr. 2026, 11:45 UTC

Résultats

Pfizer Reaffirms 2026 Guidance >PFE

3 févr. 2026, 11:45 UTC

Résultats

Pfizer 4Q Rev $17.56B >PFE

3 févr. 2026, 11:45 UTC

Résultats

Pfizer Sees FY Adj EPS $2.80-Adj EPS $3.00 >PFE

3 févr. 2026, 11:45 UTC

Résultats

Pfizer 4Q Adj EPS 66c >PFE

3 févr. 2026, 11:45 UTC

Résultats

Pfizer 4Q Loss/Shr 29c >PFE

3 févr. 2026, 11:45 UTC

Résultats

Pfizer 4Q Loss $1.65B >PFE

3 févr. 2026, 11:45 UTC

Résultats

Pfizer Sees FY Rev $59.5B-$62.5B >PFE

3 févr. 2026, 10:41 UTC

Résultats

These Stocks Are Today's Movers: Palantir, Teradyne, Tesla, AMD, NXP Semiconductors, DaVita, and More -- Barrons.com

20 janv. 2026, 07:13 UTC

Acquisitions, Fusions, Rachats

GSK PLC: Agreement Simplifies ViiV's Shareholder Structure

20 janv. 2026, 07:13 UTC

Acquisitions, Fusions, Rachats

GSK PLC to Get Special Div of $0.250B

20 janv. 2026, 00:21 UTC

Acquisitions, Fusions, Rachats

Shionogi to Acquire Additional Shares in ViiV Healthcare for $2.1B

12 janv. 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

Comparaison

Variation de prix

Pfizer prévision

Objectif de Prix

By TipRanks

4.46% hausse

Prévisions sur 12 Mois

Moyen 28.81 USD  4.46%

Haut 35.46 USD

Bas 25 USD

Basé sur 19 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

19 ratings

6

Achat

13

Maintien

0

Vente

Score Technique

By Trading Central

22.855 / 23.85Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

116 / 351Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat